Gain insights into Amneal Pharmaceuticals' Q2 2025 success, with strong growth, upgraded guidance, and promising launches like CREXONT and Brekiya.

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively ...